The DOI matches its Crossref record; 63 of the 70 references it cites were found in a registry or an index.
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α
Open accessAbstract
The switch to an angiogenic phenotype is a fundamental determinant of neoplastic growth and tumor progression. We demonstrate that homozygous deletion of the p53 tumor suppressor gene via homologous recombination in a human cancer cell line promotes the neovascularization and growth of tumor xenografts in nude mice. We find that p53 promotes Mdm2-mediated ubiquitination and proteasomal degradation of the HIF-1α subunit of hypoxia-inducible factor 1 (HIF-1), a heterodimeric transcription factor that regulates cellular energy metabolism and angiogenesis in response to oxygen deprivation. Loss of p53 in tumor cells enhances HIF-1α levels and augments HIF-1-dependent transcriptional activation of the vascular endothelial growth factor (VEGF) gene in response to hypoxia. Forced expression of HIF-1α in p53-expressing tumor cells increases hypoxia-induced VEGF expression and augments neovascularization and growth of tumor xenografts. These results indicate that amplification of normal HIF-1-dependent responses to hypoxia via loss of p53 function contributes to the angiogenic switch during tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Apart from canonical HRE-mediated transcription, the HIF isoforms differentially modulate signaling pathways through interaction with proteins that do not contain PAS domains, such p53, the c-MYC proto-oncogene, β-catenin and the Notch intracellular domain (Fig. 2A) [11–15].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Intriguingly, p53 can also promote Mdm2-mediated degradation of HIF-1α (Ravi et al., 2000).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Ravi et al., 2000
The cited source says what the claim attributes to it.
In the citing paper
“It has been proposed that MDM2 can also ubiquitinate and degrade HIF-1α through the proteasome pathway”
From Stress Response of Glioblastoma Cells Mediated by miR-17-5p Targeting PTEN and the Passenger Strand miR-17-3p Targeting MDM2 (2012) · cites this paper as [56]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“which raises the possibility that miR-17 mediates cellular response to diverse stimuli by targeting closely related signaling pathways [56].”
From Stress Response of Glioblastoma Cells Mediated by miR-17-5p Targeting PTEN and the Passenger Strand miR-17-3p Targeting MDM2 (2012) · cites this paper as [56]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Self-citationThe tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981
Self-citationKim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“…ligase and is itself a target for Ub-mediated degradation via its interaction with Mdm2 (Momand et al. 1992; Barak et al. 1993; Wu et al. 1993; Haupt et al. 1997; Honda et al. 1997; Kubbutat et al. 1997), this raised the possibility that HIF-1a is recruited to Mdm2 via its interaction with p53.”
Background
Research works printed but not linked: 3
- Kubbutat, 1997, Regulation of p53 stability by Mdm2., Nature, 387, 299, 10.1038/387299a0 · DOI · Paper page
- Ravi, 1998, p53-mediated repression of nuclear factor κ-B RelA via the transcriptional integrator p 300., Cancer Res., 58, 4531
- Zhong, 1999, Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases., Cancer Res., 59, 5830
Cited by
Sorted by citations
Items 701–800 of 967
Miyata, K., Yasukawa, T., Fukuda, M., Takeuchi, T., Yamazaki, K., Sakumi, K., Tamamori‐Adachi, M., Ohnishi, Y., OHTSUKI, Y., Nakabeppu, Y., et al. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402067 · Cited by 17
Shellman, Y. G., Park, Y. L., Marr, D. G., Casper, K., Xu, Y., Fujita, M., Swerlick, R. A., & Norris, D. A. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12511.x · Cited by 17
Fujisawa, T., Watanabe, J., Kamata, Y., Hamano, M., Hata, H., & Kuramoto, H. (2003) · Experimental and Molecular Pathology · doi:10.1016/s0014-4800(03)00020-0 · Cited by 17
Hypoxia in tumors: molecular targets for anti-cancer therapeutics
Williams, K. J., Cowen, R. L., Brown, L. M., Chinje, E. C., Jaffar, M., & Stratford, I. J. (2004) · Advances in Enzyme Regulation · doi:10.1016/j.advenzreg.2003.11.019 · Cited by 18
Hashimoto, Y. K., Tsuzuki‐Nakao, T., Kida, N., Matsuo, Y., Maruyama, T., Okada, H., & Hirota, K. (2023) · Biomedicines · doi:10.3390/biomedicines11010210 · Cited by 17
Oknińska, M., Zajda, K., Zambrowska, Z., Grzanka, M., Paterek, A., Mackiewicz, U., Szczylik, C. A., Kurzyna, M., Piekiełko‐Witkowska, A., Torbicki, A., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.03.010 · Cited by 18
Glioma angiogenesis is boosted by ELK3 activating the HIF-1$$\alpha$$/VEGF-A signaling axis
Mou, Y., Yaqin, H., Xue, G., Wenjian, Z., Yang, J., Chen, L., Haiyan, C., Chao, M., Jianping, D., Penggao, D., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11069-w · Cited by 16
Lee, S., Chen, Y., Luo, H., Wu, A. A., Wilde, M., Schumacker, P. T., & Zhao, Y. (2010) · Journal of Proteome Research · doi:10.1021/pr1005179 · Cited by 16
Oncosuppressors and Oncogenes: Role in Haemangioma Genesis and Potential for Therapeutic Targeting
Mabeta, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041192 · Cited by 16
Zhang, Y., Jiang, L., Qin, N., Cao, M., Liang, X., & Wang, R. (2020) · Biochemistry and Cell Biology · doi:10.1139/bcb-2020-0090 · Cited by 16
Oxygen-sensing mechanisms in development and tissue repair
Jiang, Y., Duan, L., & Fong, G. (2021) · Development · doi:10.1242/dev.200030 · Cited by 18
Akslen, L. A., Straume, O., Geisler, S. B., Sørlie, T., Chi, J.-T., Aas, T., Børresen-Dale, A.-L., & Lønning, P. E. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.203 · Cited by 16
Robertson, E. D., Semenchenko, K., & Wasylyk, B. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_11 · Cited by 17
Over-expression of p53 mutants in LNCaP cells alters tumor growth and angiogenesis in vivo
Perryman, L., Blair, J. M., Kingsley, E. A., Szymańska, B., Ow, K. T., Wen, V. W., MacKenzie, K. L., Vermeulen, P., Jackson, P., & Russell, P. J. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.05.020 · Cited by 15
Clinical efforts to modulate angiogenesis in the adult: gene therapy versus conventional approaches
Liau, G., Su, E. J., & Dixon, K. D. (2001) · Drug Discovery Today · doi:10.1016/s1359-6446(01)01809-8 · Cited by 16
McDermott, A., & Tavassoli, A. (2024) · Transcription · doi:10.1080/21541264.2024.2417475 · Cited by 18
Nomura, S., & Komuro, I. (2020) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2020.11.010 · Cited by 16
Guo, X., Zheng, B., Wang, J., Zhao, T., & Zheng, Y. (2022) · Phytotherapy Research · doi:10.1002/ptr.7667 · Cited by 16
p53 Mutation in the Genesis of Metastasis
Yeudall, W. A. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_6 · Cited by 15
G-Quadruplexes—Novel Mediators of Gene Function
Zhou, W., Brand, N. J., & Ying, L. (2011) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-011-9258-2 · Cited by 15
Cherry, T., Longo, S. L., Tovar-Spinoza, Z. S., & Post, D. E. (2010) · Gene Therapy · doi:10.1038/gt.2010.100 · Cited by 15
Bajgelman, M. C., dos Santos, L., da Silva, G. J. J., Nakamuta, J. S., Sirvente, R. A., Chaves, M. J. F., Krieger, J. E., & Strauss, B. E. (2014) · Virology · doi:10.1016/j.virol.2014.12.009 · Cited by 15
Imaging of cancer lipid metabolism in response to therapy
Arlauckas, S. P., Browning, E. A., Poptani, H., & Delikatny, E. J. (2019) · NMR in Biomedicine · doi:10.1002/nbm.4070 · Cited by 15
Isoform- and Paralog-Switching in IR-Signaling: When Diabetes Opens the Gates to Cancer
Scalia, P., Giordano, A., Martini, C., & Williams, S. J. (2020) · Biomolecules · doi:10.3390/biom10121617 · Cited by 15
Oxygen regulates molecular mechanisms of cancer progression and metastasis
Gupta, K., Madan, E., Sayyid, M. M., Arias‐Pulido, H., Moreno, E., Kuppusamy, P., & Gogna, R. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9464-2 · Cited by 16
Faria, A. V., Junior, F. C. D. M., Marsaioli, A. J., Ferreira, M. M. C., & Cendes, F. (2010) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2010007500146 · Cited by 15
Murley, J. S., Miller, R. C., Weichselbaum, R. R., & Grdina, D. J. (2017) · Radiation Research · doi:10.1667/rr14831.1 · Cited by 15
Wang, X., Xu, Y., Chu, C.-L., Li, H., Mi, J. D., Wen, Z., Zhang, S., Wang, Q., & Quan, S. (2019) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2018-0425 · Cited by 15
Current status and perspective of antiangiogenic therapy for cancer: urinary cancer
Kanda, S., Miyata, Y., & Kanetake, H. (2006) · International Journal of Clinical Oncology · doi:10.1007/s10147-006-0565-6 · Cited by 15
Positive expression of HIF-2α/EPAS1 in invasive bladder cancer
Xia, G., Kageyama, Y., Hayashi, T., Hyochi, N., Kawakami, S., & Kihara, K. (2002) · Urology · doi:10.1016/s0090-4295(01)01607-7 · Cited by 14
Angiogenesis and Anti-angiogenic Therapy in Myelofibrosis with Myeloid Metaplasia
Arora, B., Mesa, R. A., & Tefferi, A. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190400003267 · Cited by 15
Ileiwat, Z. E., Tabish, T. A., Zinovkin, D. A., Yüzügülen, J., Arghiani, N., & Pranjol, M. Z. I. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.976677 · Cited by 14
Waghode, P., Quadir, S. S., Choudhary, D. K., Sharma, S., & Joshi, G. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01405-7 · Cited by 14
Serdemetan Antagonizes the Mdm2-HIF1α Axis Leading to Decreased Levels of Glycolytic Enzymes
Lehman, J. A., Hauck, P. M., Gendron, J. M., Batuello, C. N., Eitel, J. A., Albig, A. R., Kadakia, M., & Mayo, L. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074741 · Cited by 14
Israels, L. G., & Israels, E. D. (2006) · Birkhäuser-Verlag eBooks · doi:10.1007/3-7643-7543-4_1 · Cited by 14
Viruses as key regulators of angiogenesis
Vrancken, K., Vervaeke, P., Balzarini, J. M., & Liekens, S. (2011) · Reviews in Medical Virology · doi:10.1002/rmv.688 · Cited by 16
Glucose transporter 1 expression in canine osteosarcoma
Petty, J., Lana, S. E., Thamm, D. H., Charles, J. B., Bachand, A. M., Bush, J. M., & Ehrhart, E. J. (2008) · Veterinary and Comparative Oncology · doi:10.1111/j.1476-5829.2007.00155.x · Cited by 14
Characterization of HIF-1α overexpressing HeLa cells and implications for gene therapy
Höfer, T., Desbaillets, I., Höpfl, G., Wenger, R. H., & Gassmann, M. (2002) · Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology · doi:10.1016/s1532-0456(02)00117-5 · Cited by 15
Son, Y., Lim, D., Park, S., Song, I., Kim, J.-H., Shin, S., Jang, H., Liu, K., Yuseok, O., Song, G., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105146 · Cited by 14
Chen, H., Cao, D., Han, N., Zhang, M., Jiang, W., Wang, X., Zeng, Q., & Tang, H. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s436926 · Cited by 13
Self-citationHuang, Y., Gao, Y., Lin, Z., & Miao, H. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101240 · Cited by 14
Novel radiogenomics approach to predict and characterize pneumonitis in stage III NSCLC
Delasos, L., Khorrami, M., Viswanathan, V. S., Jazieh, K., Ding, Y., Mutha, P., Stephans, K. L., Gupta, A. B., Pennell, N. A., Patil, P. D., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00790-9 · Cited by 14
p53 codon 72 polymorphism and endometriosis: a meta-analysis
Jia, S., Xu, L., Chan, Y., Wu, X., Yang, S., Yu, H., Yang, H., Luo, Y., & Tang, W. (2012) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-012-2226-5 · Cited by 14
Wu, J., Zhu, Y., XU, C., Xu, H., Zhou, X., Yang, J., Xie, Y., & Tao, M. (2015) · Oncology Reports · doi:10.3892/or.2015.4385 · Cited by 13
Lack of association between p53 codon 72 polymorphism and endometrial cancer: A meta-analysis
Tang, W., He, X., Chan, Y., & Luo, Y. (2012) · Cancer Epidemiology · doi:10.1016/j.canep.2011.12.010 · Cited by 13
Hotani, T., Mizuguchi, H., & Sakurai, F. (2018) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2018.12.012 · Cited by 13
Shao, N., Han, Y., Song, L., & Song, W. D. (2020) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_781_19 · Cited by 13
Proanthocyanidins as a Potential Novel Way for the Treatment of Hemangioma
Tang, R., Xian, D., Xu, J., Peng, H., Pan, S., & Zhong, J. (2021) · BioMed Research International · doi:10.1155/2021/5695378 · Cited by 13
MicroRNA‑10b modulates cisplatin tolerance by targeting p53 directly in lung cancer cells
Lin, C., Liao, W., Yang, T., Lu, H., Hsu, S., & Wu, C. (2021) · Oncology Reports · doi:10.3892/or.2021.8118 · Cited by 14
Xiong, Y., Xu, S. S., Fu, B., Tang, W., Zaky, M. Y., Tian, R., Yao, R., Zhang, S., Zhao, Q., Nian, W., et al. (2022) · Food and Chemical Toxicology · doi:10.1016/j.fct.2022.113321 · Cited by 13
Regulation of collagen-derived antiangiogenic factors by p53
Assadian, S., & Teodoro, J. G. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.7.941 · Cited by 13
Significance of p53 and CD31 in astrogliomas
Khattab, A.-Z. M., Ahmed, M., Fouad, M. M., & Essa, W. M. E.-H. (2008) · Medical Oncology · doi:10.1007/s12032-008-9094-7 · Cited by 13
Hicks, K. C., & Patel, T. B. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.714139 · Cited by 14
VEGF Expression and its Reguration by p53 Gene Transfection in Endometrial Carcinoma Cells
Fujisawa, T., Watanabe, J., Kamata, Y., Hamano, M., Hata, H., & Kuramoto, H. (2003) · Human Cell · doi:10.1111/j.1749-0774.2003.tb00128.x · Cited by 13
Anti-angiogenic agents for the treatment of brain tumors
Fisher, M. J., & Adamson, P. C. (2002) · Neuroimaging Clinics of North America · doi:10.1016/s1052-5149(02)00035-7 · Cited by 13
Vasculogenesis and Angiogenesis
Sato, T. N., & Loughna, S. (2002) · Elsevier eBooks · doi:10.1016/b978-012597951-1/50014-7 · Cited by 13
Kaur, M., Kaur, R., Chhabra, K., & Khetarpal, P. (2023) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.14701 · Cited by 12
Jurišić, A., Sung, P., Wappett, M., Daubriac, J., Lobb, I. T., Kung, W., Crawford, N., Page, N., Cassidy, E., Feutren‐Burton, S., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1648 · Cited by 13
Tang, Q., Xu, Q., Ding, C., Zhang, H., Ling, Y., Wu, C., & Fang, M. (2021) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00052.2020 · Cited by 13
Molecular mechanisms of long noncoding RNAs associated with cervical cancer radiosensitivity
Wu, S., Zhu, H., Wu, Y., Wang, C., Duan, X., & Xu, T. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2022.1093549 · Cited by 13
Targeting Altered Metabolism—Emerging Cancer Therapeutic Strategies
Seo, M., Crochet, R. B., & Lee, Y. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-396521-9.00014-0 · Cited by 13
Wang, G., Dong, Y., Liu, H., Ji, N., Cao, J., Liu, A., Tang, X., & Ren, Y. T. (2022) · Bioengineered · doi:10.1080/21655979.2022.2077906 · Cited by 12
Microvessel density of malignant and benign hepatic lesions and MRI evaluation
Lu, J. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i12.1730 · Cited by 12
Šteiner, P., Hora, M., Stehlík, J., Martínek, P., Vaněček, T., Petersson, F., Michal, M., Korabečná, M., Trávníček, I., & Hes, O. (2013) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-012-1367-z · Cited by 9
Wang, Y., Wang, Z., Piha-Paul, S. A., Jankú, F., Subbiah, V., Shi, N., Hess, K. R., Broaddus, R. R., Shan, B., Naing, A., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25947 · Cited by 11
Choe, J. H., Mazambani, S., Kim, T. H., & Kim, J. (2021) · Cells · doi:10.3390/cells10030606 · Cited by 14
Foglietta, F., Gola, G., Biasibetti, E., Capucchio, M. T., Bruni, I., Francovich, A., Durando, G., Serpe, L., & Canaparo, R. (2021) · Pharmaceuticals · doi:10.3390/ph14100972 · Cited by 11
Tumor Hypoxia and Targeted Gene Therapy
Greco, O., & Scott, S. D. (2007) · International review of cytology · doi:10.1016/s0074-7696(07)57005-1 · Cited by 11
Fukuda, M., Kusama, K., & Sakashita, H. (2011) · Japanese Dental Science Review · doi:10.1016/j.jdsr.2011.08.001 · Cited by 11
Yamazaki, K., & Eyden, B. P. (2006) · Ultrastructural Pathology · doi:10.1080/01913120500407960 · Cited by 11
Sueoka, E., Sueoka‐Aragane, N., Sato, A., Ide, M., Nakamura, H., Sotomaru, Y., Taya, C., Yonekawa, H., Kitagawa, T., Kubota, Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057833 · Cited by 11
Synergy Between VEGF/VEGFR Inhibitors and Chemotherapy Agents in the Phase I Clinic
Tang, C. Z., Hess, K. R., Jardim, D. L. F., Gagliato, D. D. M., Tsimberidou, A. M., Falchook, G. S., Fu, S., Jankú, F., Naing, A., Piha-Paul, S. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1582 · Cited by 11
Liang, Z.-L., Zhang, X.-Y., Wang, F., Zhang, K., Liu, H., & Liu, H. (2018) · Medicine · doi:10.1097/md.0000000000011886 · Cited by 11
Life-Long Effects of Perinatal Asphyxia on Stress-Induced Proteins and Dynamin 1 in Rat Brain
Kitzmüller, E., Krapfenbauer, K., Hoeger, H., Weitzdoerfer, R., Lübec, G., & Lubec, B. (2004) · Neurochemical Research · doi:10.1023/b:nere.0000035813.73790.b5 · Cited by 11
Effects of Environmental pH on the Growth of Gastric Cancer Cells
Li, W., Zhou, Y., Shang, C., Sang, H., & Zhu, H. Y. (2020) · Gastroenterology Research and Practice · doi:10.1155/2020/3245359 · Cited by 11
Interactions between HIF-1 and Jab1: Balancing Apoptosis and Adaptation
Larsen, M., Høg, A. M., Lund, E. L., & Kristjansen, P. E. G. (2006) · Springer eBooks · doi:10.1007/0-387-26206-7_28 · Cited by 11
Biswas, S., Killick, E., Jochemsen, A. G., & Lunec, J. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.892924 · Cited by 11
Influences of the p53 Status on Hypoxia-induced Gene Expression
Liu, J., Shibata, T., Qu, R., Ogura, M., & Hiraoka, M. (2004) · Journal of Radiation Research · doi:10.1269/jrr.45.333 · Cited by 12
Weak HIF-1alpha expression indicates poor prognosis in resectable pancreatic ductal adenocarcinoma
Leppänen, J., Helminen, O., Huhta, H. I., Kauppila, J. H., Isohookana, J., Haapasaari, K., Parkkila, S., Saarnio, J., Lehenkari, P. P., & Karttunen, T. J. (2018) · World Journal of Surgical Oncology · doi:10.1186/s12957-018-1432-4 · Cited by 10
Hypoxia-inducible factor-1α as prognostic marker
Lassoued, A. B., Beaufils, N., Dalès, J.-P., & Gabert, J. A. (2012) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2012.719022 · Cited by 11
Molecular targets as therapeutic strategies in the management of breast cancer
Sartor, C. I. (2002) · Seminars in Radiation Oncology · doi:10.1053/srao.2002.35253 · Cited by 10
Zhao, K., Karimi, A., Kelly, L., Petre, E. N., Marinelli, B. S., Alexander, E. S., Sotirchos, V. S., Erinjeri, J. P., Covey, A. M., Sofocleous, C. T., et al. (2025) · Current Oncology · doi:10.3390/curroncol32010051 · Cited by 9
Development of small molecule inhibitors of hypoxia-inducible factors for cancer therapy
Semenza, G. L. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100075 · Cited by 10
Self-citationKim, I., Choi, S., Yoo, S., Lee, M., & Park, J. (2022) · BMB Reports · doi:10.5483/bmbrep.2022.55.6.017 · Cited by 9
Kawata, Y., Nagasaka, K., Oda, K., Makii, C., Takeuchi, M., Oki, S., Honjo, H., Kojima, M., Miyagawa, Y., Taguchi, A., et al. (2020) · Cancer Science · doi:10.1111/cas.14583 · Cited by 9
Interaction between morphology and angiogenesis in human early colorectal cancers
Okada, K., Satoh, T., Fujimoto, K., & Tokunaga, O. (2004) · Pathology International · doi:10.1111/j.1440-1827.2004.01650.x · Cited by 9
p53 Inhibits Vascular Endothelial Growth Factor Expression in Solid Tumor
Yoshioka, Y., Shimizu, S., Ito, T., Taniguchi, M., Nomura, M., Nishida, T., & Sawa, Y. (2011) · Journal of Surgical Research · doi:10.1016/j.jss.2010.12.028 · Cited by 9
Huilan, Z., Zhenxiang, Z., Xu, Y., Lihua, X., Jianbo, L., Li, J., & Qing, T. (2004) · Current Medical Science · doi:10.1007/bf02885408 · Cited by 9
Clinical Link Between p53 and Angiogenesis in Lung Cancer
Freemantle, S. J., & Dmitrovsky, E. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.4.883 · Cited by 9
Osada‐Oka, M., Kuwamura, H., Imamiya, R., Kobayashi, K., Minamiyama, Y., Takahashi, K., Tanaka, M., & Shiota, M. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174845 · Cited by 7
Nemoto, S., Taguchi, K., Matsumoto, T., Kamata, K., & Kobayashi, T. (2011) · Peptides · doi:10.1016/j.peptides.2011.11.018 · Cited by 8
Minervini, G., Lopreiato, R., Bortolotto, R., Falconieri, A., Sartori, G., & Tosatto, S. C. E. (2017) · Scientific Reports · doi:10.1038/srep46562 · Cited by 10
Arokiaraj, M. C. (2017) · BMC Cardiovascular Disorders · doi:10.1186/s12872-017-0643-x · Cited by 8
Mao, J., Deng, D., Yang, Z., Wang, W., Cao, M., Huang, Y., & Shen, J. (2020) · British Journal of Radiology · doi:10.1259/bjr.20200661 · Cited by 8
Ikebata, A., Shimoda, M., Okabayashi, K., Uraoka, T., Maehata, T., Sugimoto, S., Mutaguchi, M., Naganuma, M., Kameyama, K., Yahagi, N., et al. (2021) · Endoscopy International Open · doi:10.1055/a-1352-2709 · Cited by 8
Shamis, S. A. K., Quinn, J. A., Mallon, E., Edwards, J., & McMillan, D. C. (2022) · Journal of Histochemistry & Cytochemistry · doi:10.1369/00221554221110280 · Cited by 8
Sathy, B. N., Chou, Y.-C., Li, H. J., Chang, C., & Chow, K.-P. N. (2009) · Laboratory Animals · doi:10.1258/la.2007.007105 · Cited by 8
Malik, A., Mishra, R., Fanthome, B., Rao, R., & Patrikar, S. (2011) · Medical Journal Armed Forces India · doi:10.1016/s0377-1237(11)60076-2 · Cited by 8
The TP53 Tumor Suppressor Gene: Structure and Function☆
Becker, K. A., & Jerry, D. J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.98757-9 · Cited by 8
Zou, Y., Wang, Z., Jiang, Q., Kong, X., Ma, X., Liang, Z., Wang, Z., Chen, B., Yuan, J., Wen, J., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2500562122 · Cited by 7
Metadata
- Authors
- Ravi, R., Mookerjee, B., Bhujwalla, Z. M., Sutter, C. H., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., & Bedi, A.
- Affiliations
- Johns Hopkins University (US)
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2000-01-01
- Volume
- 14
- Issue
- 1
- Pages
- 34-44
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W4294718043
- Semantic Scholar
- 5c0770cda1be256df47794076979768b0350af33
- Cited by
- 967
- References
- 70
- Citations by year
- 2026: 19 · 2025: 23 · 2024: 35 · 2023: 28 · 2022: 35 · 2021: 35 · 2020: 33 · 2019: 25 · 2018: 30 · 2017: 25 · 2016: 35 · 2015: 41 · 2014: 36 · 2013: 34 · 2012: 32
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Genes & Development (publishedVersion)
- Funders
- U.S. Department of Defense
- American Cancer Society
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- tumor angiogenesis, p53, hypoxia-inducible factor-1α, MDM2, ubiquitination, proteasomal degradation, vascular endothelial growth factor, hypoxia, neovascularization, tumor xenografts, angiogenic switch, tumor suppressor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
